Tigecycline for the treatment of infections due to resistant Gram-positive organisms

Expert Opinion on Investigational Drugs

Volumn 15, Issue 2, 2006, Pages 155-162

  Squires, Ronald A ^a   Postier, Russell G ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Complicated skin and soft tissue infection; Efflux; Glycylcycline; Methicillin resistant Staphylococcus aureus; Ribosomal protection; Tetracycline; Tigecycline; Vancomycin resistant enterococci

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZITHROMYCIN; AZTREONAM; CEFOXITIN; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; ERYTHROMYCIN; IMIPENEM; LINEZOLID; METICILLIN; MINOCYCLINE; ORITAVANCIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TELAVANCIN; TETRACYCLINE; TIGECYCLINE; TROVAFLOXACIN; VANCOMYCIN; WARFARIN;

ABDOMINAL INFECTION; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL INFECTION; BACTERIAL STRAIN; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROCOCCUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HIGH RISK PATIENT; HUMAN; HYPERAMYLASEMIA; IN VITRO STUDY; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NAUSEA AND VOMITING; NONHUMAN; PANCREATITIS; PARESTHESIA; PHARMACODYNAMICS; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STEADY STATE; STRUCTURE ACTIVITY RELATION; TERATOGENICITY; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

EID: 32844473440     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.2.155     Document Type: Article

References (39)

1. CARON C: MRSA and MRSE: is there an answer? Clin. Microbiol. Infect. (2000) 6(Suppl. 2):17-22.
2. KELLNER JD: Drug-resistant Streptococcus pneumoniae infections: clinical importance, drug treatment and prevention. Semin. Resp. Infect. (2001) 16:186-195.
3. POOTOOLAL J, NEU J, WRIGHT GD: Glycopeptide antibiotic resistance. Ann. Rev. Pharmacol. Toxicol. (2002) 42:381-408.
4. EDMOND M: Glycopeptide-resistant Staphylococcus aureus. Int. J. Clin. Prac. (2000) 115:66-71.
5. DIEKMA DJ, JONES RN: Oxazolidinone antibiotics. Lancet (2001) 358:1975-1982.
6. ALLINGTON DR, RIVEY MP: Quinupristin/dalfopristin: a therapeutic review. Clin. Ther. (2001) 23:24-44.
7. GUAY DRP: Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria. Pharmacotherapy (2004) 24(1):58-68.
8. MALABARBA A, CIABATTI R: Glycopeptide derivatives. Curr. Med. Chem. (2001) 8:1759-1773.
9. GIAMARELLOU H, O'RIORDAN W, HARRIS H, OWEN S, PORTER S, LOUTIT J: Phase III trial comparing 3-7 days of oritavancin versus 10-14 days of vancomycin/cephalexin in the treatment of patients with complicated skin and skin structure infections (cSSI). Program And Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA (September 14 - 17 2003) (L-739a).
10. MERCIER R-C, HREBICKOVA L: Oritavancin: a new avenue for resistant Gram-positive bacteria. Exp. Rev. Anti-infective Ther. (2005) 3(3):325-332.
11. STRYJEWSKI ME: Telavancin (TLV) versus standard therapy (ST) for treatment of complicated Gram-positive skin and soft tissue infections (cSSTI). Infectious Disease Society of America 41st Annual Meeting, San Diego, USA (October 3 2004) (Abstract 517).
12. VICURON PHARMACEUTICALS: New drug application submitted for dalbavancin to US Food and Drug Administration: once-weekly antibiotic designed to treat growing problem of hospital Staphylococcal infections (Press Release).
13. SUM P-E, PETERSEN P: Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg. Med. Chem. Lett. (1999) 9(10):1459-1462.
14. CHOPRA I, ROBERTS, M: Tetracycline antibiotics: Mode of action, applications, molecular biology, and antibacterial resistance. Microbiol. Mol. Biol. Revs (2001) 65:232-256.
15. PETERSEN PJ, JACOBUS NV, WEISS WJ, SUM PE, TESTA RT: In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycyclamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. (1999) 43(4):783-744.
16. BETRIU C, CULEBRAS E, GÓMEZ M, RODRÍGUEZ-AVIAL I, PICAZO JJ: In vitro activity of tigecycline against Bacteroides species. J. Antimicrob. Chemother. (2005) 56:349-352.
17. POSTIER RG, GREEN SL, KLEIN SR, ELLIS-CROSSE EJ, LOH E, TIGECYCLINE STUDY GROUP: Results of a multicenter, randomized, open-label efficacy study of two doses of tigecycline for complicated skin and skin structure infections in hospitalized patients. Clin. Ther. (2004) 26(5):704-714.
18. MURALIDHARAN G, GETSY J, MAYER P et al.: Pharmacokinetics (PK), safety, and tolerability of GAR-936, a novel glycylcycline antibiotic, in healthy subjects. Abstracts of the Interscience Conference on Antimicrobial Agents in Chemotherapy, San Francisco, California, USA (September 27 - 30 1999):39.
19. MURALIDHARAN G, MOJAVERIAN P, MICALIZZI M et al.: The effects of age and gender on the pharmacokinetics, safety and tolerability of GAR-936, a novel glycylcycline antibiotic, in healthy subjects. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents in Chemotherapy, Toronto, Ontario, Canada (September 17 - 20 2000) (Abstract A-502).
20. TROY SM, MURALIDHARAN G, MICALIZZI M, MOJAVERIAN P, SALACINSKI L, RAIBLE D: The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936). Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents in Chemotherapy, Chicago, Illinois, USA (September 14 - 17 2003) (Abstract A-22).
21. NANNINI EC, PAI SR, SINGH KV, MURRAY BE: Activity of tigecycline (GAR-936), a novel glycylcycline, against enterococci in the mouse peritonitis model. Antimicrob. Agents Chemother. (2003) 47(2):529-532.
22. SESOKO S, UMEMURA K, NAKASHIMA M: Pharmacokinetics (PK), safety and tolerability of tigecycline (GAR-936) in healthy Japanese males. Abstracts of the Interscience Conference on Antimicrobial Agents in Chemotherapy, San Diego, California, USA (September 27 - 30 2002) (Abstract A-1403).
23. MURRAY J, WILSON S, KLEIN S, YELLIN A, LOH E: The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients, a Phase II clinical trial. Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents in Chemotherapy, Washington, DC, USA (2003) (Abstract L-739).
24. PROJAN SJ: Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy (2000) 20(9):219S-223S.
25. MILATOVIC D, SCHMITZ F, VERHOEF J, FLUIT A: Activities of the glycylcycline tigecycline (GAR-936) against 1.924 recent European clinical bacterial isolates. Antimicrob. Agents Chemother. (2003) 47(1):400-404.
26. WALLACE R, BROWN-ELLIOTT B, CRIST C, MANN L, WILSON R: Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob. Agents Chemother. (2002) 46(10):3164-3167.
27. EDELSTEIN P, WEISS W, EDELSTEIN M: Activities of tigecycline (GAR-936) against Legionella pneumophilia in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother. (2003) 47(2):533-540.
28. JACOBUS N, McDERMOTT L, RUTHAZER R, SNYDMAN D: In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob. Agents Chemother. (2004) 48(3):1034-1036.
29. CHOPRA I: Glycylcylines: third-generation tetracycline antibiotics. Curr. Opin. Pharmacol. (2001) 1(5):464-469.
30. ZHANEL GG, HOMENUIK K, NICHOL K et al.: The glycylcyclines: a comparative review with the tetracyclines. Drugs (2004) 64(1):63-88.
31. BRADFORD PA, WEAVER-SANDS DT, PETERSEN PJ: In vitro activity of tigecycline against isolates from patietns enrolled in Phase III clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin. Infect. Dis. (2005) 41:S315-S332.
32. DARTOIS N: Results of a Phase III, double-blind, safety and efficacy study comparing tigecycline with vancomycin/aztreonam to treat complicated skin and skin structure infections. 44th Annual Meeting of the Interscience Conference on Antimicrobial Agents in Chemotherapy, Washington DC, USA (2004) (Session 97; Control 3841; Presentation L-986).
33. DARTOIS N, GIOUD-PAQUET M, ELLIS-GROSSE EJ et al.: Tigecycline versus imipenem/cilastatin for treatment of complicated intra-abdominal infections. 44th Annual Meeting of the Interscience Conference on Antimicrobial Agents in Chemotherapy, Washington, DC, USA (2004) (Session 97; Control 3841; Presentation L-992c).
34. ROSE G, LOH E: Efficacy and safety of tigecycline compared with vancomycin/aztreonam in patients with complicated skin and skin structure infections: Results from a Phase III, randomized, double-blind trial. 11th International Symposium on Staphylococci and Staphylococcal Infections, Charleston, USA (October 24 - 27 2004) (Presentation TH-13).
35. ELLIS-GROSSE EJ, LOH E on behalf of tigecycline 301 study group: Tigecycline compared with imipenem/cilastatin in the treatment of complicated intra-abdominal infections. 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark (April 2 - 5 2005).
36. FOMIN P, BEURAN M, GRADAUSKAS A et al. on behalf of the 306 Study Group: Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int. J. Surgery (2005) 3:35-47.
37. SACCHIDANAND, PENN S, EMBIL RL et al. for the Tigecycline Study 300 Trial Group: Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase III, randomized, double-blind trial. Int. J. Infect. Dis. (2005) 9(5):251-261.
38. OLIVA ME, REKHA A, YELLIN A et al.: A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infect. Dis. (2005) 5:88.
39. BREEDT J, TERAS J, GARDOVSKIS J et al.: The safety and efficacy of tigecycline in the treatment of skin and skin structure infections: results of a double-blind Phase III comparison study with vancomycin/aztreonam. Antimicrob. Agents Chemother. (2005) 49(11):4658-4666.